|Bid||7.45 x 0|
|Ask||7.58 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IM Cannabis becomes third Israeli cannabis listing in past six weeks Toronto, Ontario--(Newsfile Corp. - November 5, 2019) - The Canadian Securities Exchange ("CSE" or "the Exchange") welcomes the listing of three Israel-based companies on the Exchange over the past six weeks: InnoCan Pharma Corp. (CSE: INNO), Isracann Biosciences Inc. (CSE: IPOT), and IM Cannabis Corp. (CSE: IMCC), which began trading today. ...
TORONTO, Nov. 4, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDD) (FRA:0K9.F - News) ("FSD" or the "Company") announces that it has closed a second tranche of its previously announced private placement (the "Private Placement"), and has now raised total gross proceeds of CAD $4,596,285 from investors, including members of senior management and the Board of Directors, issuing an aggregate of 228,671 class B subordinate voting shares (the "Shares"). The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws. The Company expected to close the Private Placement by October 31, 2019, however, it has elected to extend the Private Placement to accommodate potential additional interest from institutional grade investors.
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - Executive Co-Chairman and CEO of FSD Pharma, Dr. Raza Bokhari, speaks about the company's sales license which allows FSD to serve the growing medicinal user market in Canada.If you cannot view the video above, please visit:https://www.b-tv.com/fsd-pharma-sales-license-ceo-clip-90sec/FSD Pharma Inc. (CSE: HUGE)fsdpharma.comAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 second video profiles ...
TORONTO, Oct. 23, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company") announces that an amended and restated management's discussion and analysis for the year ended December 31, 2018 (the "Amended 2018 MD&A") has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission ("OSC") of the Company's disclosure record. The Amended 2018 MD&A was filed to address comments received from OSC staff and in order to improve the Company's disclosure.
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2019) - Today's feature company is FSD Pharma Inc. (CSE:HUGE) (FSE:0K9) (OTCQB:FSDDD), which is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.InvestmentPitch.com has produced a "video" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and ...
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDD) announced that its Class B shares, which trade on the OTCQB, will have a new symbol FSDDD for a period of 20 business days until November 13th, at which time the symbol will revert back to FSDDF. The temporary change is protocol for stocks that trade on US exchanges that undergo structural events, such as ...
TORONTO , Oct. 17, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDD) (FRA: 0K9) ("FSD" or the "Company") today announced that the Company's Class B Shares are trading on the OTCQB ...
TORONTO, Oct. 11, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company") today announced the appointment of former U.S. congressman Stephen Buyer to the Company's Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares ("Class A Shares") and its class B subordinate voting shares ("Class B Shares" and collectively with the Class A Shares, the "FSD Shares"), each on a 1 to 201 basis (the "Consolidation").
FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") is pleased to provide an update on its previously announced private placement of its class B subordinate voting shares (“Shares”) at a price of CAD$0.10 per Share (the “Private Placement”). On September 30, 2019, the Company closed an initial tranche of the Private Placement, raising gross proceeds of CAD $4,583,085 from investors, including members of senior management and board of directors, and issuing an aggregate of 45,830,850 Shares. The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws.
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), through its wholly-owned subsidiary FV Pharma, has signed a letter of intent with World Class Extractions (CSE: PUMP) (FSE: WCF) to create a joint venture to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario. FSD Pharma and World Class Extractions will each hold a 50% interest in the new joint venture, ...
TORONTO, Sept. 25, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC:FSDDF - News) (FRA: 0K9) ("FSD Pharma", "FSD" or "the Company") today announced the signing of a letter of intent ("LOI") to establish a joint venture (the "Joint Venture") with the Company's wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), and World-Class Extractions Inc. ("World-Class") (CSE:PUMP) (FRA:WCF.F - News) to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario (the "Facility") to extract various cannabidiol and other valuable elements from cannabis and hemp plants.
FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) has launched its online ordering system for the direct fulfillment of medicinal cannabis orders. Clients having a prescription from a medical practitioner or a registration number with Health Canada can now place an order online for dried cannabis on FVPharma.com. FSD Pharma subsidiary FV Pharma will handle the system. "The launch of a functional online ordering portal […]The post FSD Pharma Launches Online System for Medicinal Cannabis Orders appeared first on Market Exclusive.
TORONTO, Aug. 30, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA:0K9.F - News) ("FSD" or the "Company") is pleased to announce that the Company has launched a private placement of up to US$5 million of its class B subordinate voting shares ("Shares") at a price of C$0.10 per Share without any warrant coverage (the "Private Placement"). The Company expects to close the Private Placement by September 30, 2019. To date, C$1,314,000 million of proceeds have been committed and received. The CEO has personally invested US$500,000 and the FSD Pharma leadership team, representing founders, directors and members of the senior management team have collectively invested more than C$500,000.
Orders for medicinal cannabis can be placed on fvpharma.com TORONTO , Aug. 21, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") today announced the ...
Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF) is pleased to provide an operational update on Pharmadrug Production GmbH (the “German Business” or “Pharmadrug”) and additional resources allocated to investor relations. Following Aura’s German operational update on June 5, 2019, Pharmadrug received its second, much larger shipment of medical cannabis from Netherlands at the end of June.
Leo Acquisitions Corp. (LEQ-H.V) (“Leo” or the “Company”) and CBx Brands Inc. (“CBx”) are pleased to announce that they have entered into a letter of intent (the “LOI”), dated July 10, 2019, pursuant to which the Company and CBx have agreed to complete a transaction (the “Transaction”) that will result in a reverse take-over of the Company by the shareholders of CBx. It is intended that the Transaction will constitute the "Qualifying Transaction" of the Company as such term is defined in Policy 2.4 of the Corporate Finance Manual (the “Policy”) of the TSX Venture Exchange (the “TSXV”).
FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) and US-based specialty R&D pharmaceutical company Prismic Pharmaceuticals finalized a deal for the acquisition of all of the issued and outstanding securities of Prismic by FSD Pharma. Under to the terms of a securities exchange agreement, FSD Pharma has acquired all outstanding common and preferred shares of […]The post FSD Pharma Acquires Prismic Pharmaceuticals appeared first on Market Exclusive.